Zymeworks (ZYME) announced that the National Medical Products Administration in China has approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. The conditional approval marks the first and only1 dual HER2-targeted bispecific antibody approved for HER2-high expression BTC in China. Zymeworks’ collaboration partner, BeOne Medicines Ltd., obtained the conditional approval under the terms of its Asia Pacific license and collaboration agreement with Zymeworks. Continued approval of this indication will depend on the verification of clinical benefit in the patient population through ongoing confirmatory trials.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks Showcases Oncology Advances at Major Conferences
- Zymeworks to Engage Investors at Upcoming Conferences
- MongoDB and Asana downgraded: Wall Street’s top analyst calls
- Zymeworks: Hold Rating Maintained Amid Financial Improvements and Early-Stage Growth Potential
- Zymeworks: Buy Rating Driven by Innovative Pipeline and Strategic Partnerships